|Last Price$24.12||Day Change (%)2.03%|
|Open Price$23.80||Day Change ($)0.48|
|Day Range23.47–24.15||52-Week Range19.79–36.96|
As of Mon 5/2/2016 5:26:00 PM | USD
Onco360 Chosen for Highly Select VENCLEXTA(TM) (VENETOCLAX) Pharmacy Network
Investment Advisor magazine’s Editor-in Chief John Sullivan talks with Envestnet | PMC Investment Analyst Chris Devaney about the research behind the selection of the nominees and winners in the Mid-Cap Equity category.
The assumptions, opinions and estimates in this report constitute our judgment as of the date of this material and are subject to change without notice. The comments should not be construed as a recommendation of individual holdings or market sectors, but as an illustration of the management ...
CA new software vision provides strategic focus, but growth remains elusive.
Plus, BlackRock and Fidelity target-date fund news, and more.
Goldman Sachs funds' group suffers another departure and more.
Week ending July 21